INT264641

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2005
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 25
Total Number 25
Disease Relevance 18.56
Pain Relevance 6.98

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (AES)
Anatomy Link Frequency
B cells 1
vessels 1
AES (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 20 99.98 Very High Very High Very High
Multiple sclerosis 264 99.76 Very High Very High Very High
pregabalin 54 99.76 Very High Very High Very High
Opioid 29 99.76 Very High Very High Very High
headache 82 99.64 Very High Very High Very High
Triptan 64 99.60 Very High Very High Very High
aspirin 16 99.20 Very High Very High Very High
Sumatriptan 94 98.74 Very High Very High Very High
cva 15 98.16 Very High Very High Very High
abdominal pain 4 95.40 Very High Very High Very High
Disease Link Frequency Relevance Heat
Conjunctiva Disease 4 100.00 Very High Very High Very High
Conjunctivitis 2 100.00 Very High Very High Very High
Uveitis 2 100.00 Very High Very High Very High
INFLAMMATION 19 99.98 Very High Very High Very High
Infection 175 99.84 Very High Very High Very High
Demyelinating Disease 267 99.76 Very High Very High Very High
Headache 186 99.64 Very High Very High Very High
Vomiting 84 99.40 Very High Very High Very High
Phobia 12 99.36 Very High Very High Very High
Fatigue 26 99.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In many studies investigating the AEs typically associated with the triptans, almotriptan was found to show a good safety profile, comparable with that of placebo.
AEs Binding (associated) of associated with triptan
1) Confidence 0.42 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656322 Disease Relevance 0.87 Pain Relevance 1.03
Recommended supportive care measures for managing AEs associated with bisphosphonate therapy are presented in Table 1.2,25,26

Quality of life

AEs Binding (associated) of
2) Confidence 0.38 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC3003608 Disease Relevance 0.53 Pain Relevance 0.15
Ocular inflammatory AEs (conjunctivitis, episcleritis, uveitis, or scleritis) are occasionally associated with nitrogen-containing bisphosphonates (particularly with regimens used in cancer) and may be mediated by tumor necrosis factor-?
AEs Binding (associated) of associated with necrosis, conjunctivitis, conjunctiva disease, inflammation, cancer and uveitis
3) Confidence 0.38 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682394 Disease Relevance 1.75 Pain Relevance 0.13
As B cells clear after the first infusion, the risk factors for AEs decline dramatically with further infusions [10].
AEs Binding (decline) of in B cells
4) Confidence 0.31 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833973 Disease Relevance 1.15 Pain Relevance 0.04
On the contrary, almotriptan dislayed a lower contractile effect compared to sumatriptan on vessels (ie, coronary arteries) suggested to be related to AEs associated with the triptans (Bou et al 2001).
AEs Binding (associated) of in vessels associated with sumatriptan and triptan
5) Confidence 0.31 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656322 Disease Relevance 0.45 Pain Relevance 0.93
The risk factors for severe AEs associated with use of rituximab are well defined.
AEs Binding (associated) of
6) Confidence 0.30 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833973 Disease Relevance 1.10 Pain Relevance 0.13
Furthermore, only a small subset of 12 AEs were associated with these drugs.
AEs Binding (associated) of
7) Confidence 0.29 Published 2010 Journal BMC Bioinformatics Section Body Doc Link PMC2967748 Disease Relevance 0.25 Pain Relevance 0.04
Roughly, RR=1 indicates that the drugs and AEs are statistically independent, RR>1 that the drugs and AEs are positively correlated, and RR<1 that the drugs and AEs are negatively correlated.
AEs Binding (independent) of
8) Confidence 0.29 Published 2010 Journal BMC Bioinformatics Section Body Doc Link PMC2967748 Disease Relevance 0 Pain Relevance 0
In our context this means that if a certain combination of drugs and AEs is infrequent, then any larger combination that builds upon the smaller infrequent one, will also be infrequent, and thus need not be considered.
AEs Binding (combination) of
9) Confidence 0.29 Published 2010 Journal BMC Bioinformatics Section Body Doc Link PMC2967748 Disease Relevance 0.08 Pain Relevance 0.16
Aside from the AEs associated with MS therapies, some patients also find the process of regular self-injection burdensome, and adherence can be compromised as a result.
AEs Binding (associated) of associated with multiple sclerosis
10) Confidence 0.29 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC2819898 Disease Relevance 0.76 Pain Relevance 0.16
For example, in addition to ensuring that bisphosphonates are administered in a safe and consistent manner, the monthly infusion visit allows the oncology nurse to educate the patient about potential AEs associated with therapy.
AEs Binding (associated) of
11) Confidence 0.28 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC3003608 Disease Relevance 0.11 Pain Relevance 0.12
excluding from analysis the possibility of multi-item associations, e.g. an association between two drugs and one or two AEs, such as
AEs Binding (association) of
12) Confidence 0.28 Published 2010 Journal BMC Bioinformatics Section Body Doc Link PMC2967748 Disease Relevance 0.19 Pain Relevance 0.05
These AEs are commonly associated with opioid therapy.
AEs Binding (associated) of associated with opioid
13) Confidence 0.24 Published 2010 Journal Annals of Oncology Section Body Doc Link PMC2875549 Disease Relevance 1.58 Pain Relevance 0.62
The AEs most frequently leading to discontinuation were IRs, followed by infections.
AEs Binding (followed) of associated with infection
14) Confidence 0.24 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911915 Disease Relevance 0.33 Pain Relevance 0.18
Although an association towards a greater rate of AEs was observed in patients who continued to smoke during therapy, this was not statistically significant.
AEs Binding (association) of
15) Confidence 0.23 Published 2011 Journal Journal of Cancer Section Body Doc Link PMC3020361 Disease Relevance 1.24 Pain Relevance 0
Once an acute exacerbation has been controlled, the focus of treatment becomes prevention of recurrence, preservation of functioning and minimization of AEs associated with long-term medication exposure.
AEs Binding (associated) of associated with recurrence
16) Confidence 0.21 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656329 Disease Relevance 0.38 Pain Relevance 0
The incidence of AEs associated with MS therapy tends to decrease the longer a patient is on therapy.
AEs Binding (associated) of associated with multiple sclerosis
17) Confidence 0.21 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC2819898 Disease Relevance 0.52 Pain Relevance 0.20
AEs associated with MS therapy may also contribute to non-adherence to treatment regimens.
AEs Binding (associated) of associated with multiple sclerosis
18) Confidence 0.21 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC2819898 Disease Relevance 0.59 Pain Relevance 0.23
The most commonly reported AEs associated with pregabalin treatment were dizziness (range 16-66%) and somnolence (range 15-40%) [27,29,33,34].
AEs Binding (associated) of associated with pregabalin and dizziness
19) Confidence 0.18 Published 2010 Journal BMC Neurol Section Body Doc Link PMC3003252 Disease Relevance 0.63 Pain Relevance 1.78
Of these, 1,322 events were temporally associated AEs (defined as occurring between the start of infusion and 72 hours after the end of infusion), and 1,338 events were considered at least possibly related to study medication.
AEs Binding (associated) of
20) Confidence 0.14 Published 2010 Journal J Clin Immunol Section Body Doc Link PMC2935975 Disease Relevance 0.07 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox